Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster...

Related Keywords

California ,United States ,Stanford University ,New York ,San Francisco ,Alabama ,American ,Vivian Wu ,Jonathan Zalevsky ,David Rosen ,American Society Of Hematology ,Research Development ,Exchange Commission On ,Nektar Therapeutics ,Duke Cancer Institute ,Fred Hutchinson Cancer Center ,Cairo Laboratory At New York Medical College ,Md Anderson Cancer Center ,Rituximab Resistant Burkitt Lymphoma ,Cairo Laboratory ,New York Medical College ,American Society ,Annual Meeting ,Natural Killer ,Senior Vice President ,Chief Research ,Development Officer ,Ex Vivo Expanded ,Cellular Cytotoxicity By Obinutuzumab Combined ,Burkitt Lymphoma ,Hutchinson Cancer Center ,Cancer Center ,Annual Report ,Exchange Commission ,